Autopsy report · NCT04163718

TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)

“Drug no longer available”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 11 months before it stopped.
• 12 participants enrolled.
• Results were posted on the registry 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Sponsor type

University, hospital or other

Conditions

Chronic Lymphocytic Leukemia

Interventions

Umbralisib

Participants

12

Sites

1

Countries

United States

Trials that died the same way

• Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer
  “Drug was no longer available” (95% match in meaning)
• Role of Oxytocin in Telling and Detecting Lies
  “Drug not available” (89% match in meaning)
• BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome
  “Drug unavailable” (87% match in meaning)
• CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
  “Study drug no longer available” (81% match in meaning)
• Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
  “Drug was not available.” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.